F. MHRA Actions, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA

Upon receipt of a serious breach notification, the MHRA will review and assess the notification, and a variety of actions may be taken, depending on the nature of the breach and its potential impact. In general:

1. The GCP Inspectorate checks the serious breach mailbox.

2. Receipt of the notification will be sent and a GCP Inspector will be assigned to review.

3. The Inspector is responsible for reviewing the serious breach.

4. The inspector will decide if:

  • the referral only requires to be logged with no further action (the case may be examined during future MHRA inspections).
  • further information/investigation/CAPA is required. If insufficient information is provided in the initial notification to assess the impact of the breach, follow-up information will be requested.
  • if any other bodies are required to be notified (for example, other competent authorities/EMA, Licensing Division, Clinical Trials Unit (CTU), HRA, Research Ethics Committees, other GxP areas, etc.).
  • further actions are required (for example, a referral to the MHRA Inspection Action Group if the issue is critical or trigger an inspection to investigate further).
  • referral to CTU for consideration of suspension or termination of a clinical trial authorisation.
  • referral to the MHRA Enforcement Unit for consideration of enforcement action, for example, infringement notices, criminal investigation.
  • referral to professional bodies, for example, the General Medical Council.
     

5. Once any/all required actions have been satisfactorily completed, the inspector will close the referral.

 

Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency

Clinical Research News

Estudo da Radiological Society of North America: Embolização da artéria genicular reduz a dor da artrose do joelho durante 12 meses
GLP-1 e fertilidade: Por que os medicamentos para perda de peso estão a ser discutidos na medicina reprodutiva
Novo ensaio testará combinação de medicamentos contra o risco cardíaco hereditário
Medicamentos para perda de peso associados a menor risco de certos tipos de câncer: o que mostram os novos dados
Após AVC e hemorragia cerebral: Novo estudo testa quando os anticoagulantes são necessários
Primeira vacina projetada por IA conclui testes em humanos
Blood in Urine and Suspected Tumor: New Urine Test to be Compared Against Cystoscopy and Biopsy

Próximos ensaios clínicos

Clinical Research Jobs

More jobs

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

Se inscrever